Dr. Digavalli has 18 years of drug discovery and development experience. As a Principal Scientist at the global biopharmaceutical company Bristol Myers Squibb, he led a team of in vivo biologists and delivered translational tools for neuropsychiatric, pain and gastrointestinal motility disorders. Overall, his team enabled a dozen New Chemical Entities, many of which are undergoing or completed early phase clinical trials. At ETSU, his laboratory focuses on developing and validating electroencephalography (EEG) based biomarkers for target engagement, dose-selection and patient stratification for novel neuropsychiatric drugs.
Dr. Digavalli earned his Bachelor of Science in Pharmacy and Master of Pharmacology from Kakatiya University, Warangal, India. He went on to earn a Master of Science in Toxicology from the University of Louisiana at Monroe, and a PhD in Pharmacology and Experimental Therapeutics from Louisiana State University Health Sciences Center in New Orleans. He received his postdoctoral training at Harvard Medical School’s Center for Swallowing and Motility Disorders at the West Roxbury VA Hospital. He has been an invited speaker at national and international meetings on translational biomarkers and has authored over 25 peer-reviewed publications including reviews and monographs.
Dr. Digavalli's publications listed onPubMed: